Johnson & Johnson settles Ohio lawsuits to avoid federal trial | Reuters

archive.today
webpage capture

Saved from

no other snapshots from this url |

26 Aug 2021 04:39:01 UTC

All snapshots | from host www.reuters.com
Webpage Screenshot
share download .zip report bug or abuse donate

Now Reading Johnson & Johnson settles Ohio lawsuits to avoid federal trial

- Moderna withholds 1.63 million COVID-19 vaccine doses in Ja…
  an hour ago
- Southern California students and families stranded in Afgha…
  3 hours ago
- Democrats urge Biden to fight restart of Trump immigration …
  3 hours ago
- Heart inflammation risk boosted slightly by vaccine, more b…
  3 hours ago
- U.S. House Jan. 6 committee demands Trump White House records
  4 hours ago
- 'Profound abuse': Judge disciplines pro-Trump lawyers over …
  4 hours ago
- U.S. to work with Big Tech, finance sector on new cybersecu…
  5 hours ago
- N. Korea to convene parliament as economic woes cause strain
  5 hours ago
- Fossil of previously unknown four-legged whale found in Egypt
  5 hours ago
- R Kelly accuser says R&B singer tried to shift blame to her…
  5 hours ago

Healthcare & Pharma
October 2, 2019 / 12:10 AM / Updated 2 years ago

# Johnson & Johnson settles Ohio lawsuits to avoid federal trial

By Shubham Kalia
3 Min Read
(Reuters) - Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation’s opioid epidemic.
J&J became the fourth drugmaker to settle claims ahead of the Federal Court trial against multiple manufacturers and distributors in Cleveland scheduled for later this month. The case is considered a bellwether for more than 2,600 lawsuits by state and local governments that are pending nationally.
“The settlement allows the company to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation’s opioid crisis,” J&J said in a statement.
“The company recognizes the opioid crisis is a complex public health challenge and is working collaboratively to help communities and people in need,” it added.
Opioids were involved in 400,000 overdose deaths in the United States from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
J&J which formerly marketed the painkillers Duragesic and Nucynta, said the settlement includes no admission of liability.
The company will pay $10 million to Cuyahoga and Summit counties, reimburse $5 million of their legal and other expenses and provide $5.4 million to non-profit organizations that run opioid-related programs in the counties.
Mallinckrodt Plc finalized a $24 million settlement with the same two counties on Monday. Endo International Plc and Allergan Plc also settled with the two counties in August to avoid going to trial.
The remaining defendants in the Oct. 21 federal trial include McKesson Corp, AmerisourceBergen, Cardinal Health, Teva Pharmaceutical Industries Ltd, Walgreens Boots Alliance Inc and Henry Schein Inc.
OxyContin maker Purdue Pharma LP succumbed to pressure from the lawsuits and filed for bankruptcy protection in September.
Some plaintiffs’ lawyers have compared the opioid cases to litigation by states against the tobacco industry that led to a $246 billion settlement in 1998.
Earlier in the year, an Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for its part in fueling an opioid epidemic by deceptively marketing addictive painkillers.
Purdue Pharma and Teva had settled claims by Oklahoma’s attorney general for $270 million and $85 million, respectively.
Our Standards: The Thomson Reuters Trust Principles.
Trending Stories

- Wall Street hits records on economic optimism; dollar falls
- S&P 500, Nasdaq notch all-time closing highs ahead of Jackson Hole
- Asian shares retreat from rally, South Korea raises rates
- HK stocks rise the most in 3 weeks as bargain hunters snap up tech shares
- Wall St extends rally, pushing S&P 500 to 50th all-time high close this year

0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%